← All trials
NCT05238649
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2021
- Primary completion
- Nov 30, 2022
- Completion date
- Jan 28, 2023
- First posted
- Feb 14, 2022
- Last posted
- Mar 29, 2022
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Livzon Pharmaceutical Group Inc.Lead sponsor
- Zhuhai People's Hospital Medical GroupOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.